Clinical trials: MDI
Asthma
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)
This is a 24 week study to evaluate the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler in adults and adolescents with inadequately controlled asthma.
- Trial name
- VATHOS (NCT05202262)
- Testing
- BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, BD MDI 320 μg
- Where
- 142 sites in United States, Canada and 5 more
- Volunteers
- 645 people
- Sponsor
- AstraZeneca
Asthma
Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma
The purpose of this study is to compare the efficacy and safety of the fixed combination asthma drug FlutiForm HFA MDI with its two components administered alone, fluticasone propionate and formoterol fumarate, and with placebo…
- Trial name
- NCT00393991
- Testing
- Fluticasone propionate/formoterol fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10
- Where
- 57 sites in United States, Canada
- Volunteers
- 475 people
- Sponsor
- SkyePharma AG
Asthma, Chronic Obstructive Pulmonary Disease
Reliability of a Top Mount Actuation Indicator With Levalbuterol MDI in Adult and Pediatric Subjects With Asthma or COPD
This is a study to investigate the reliability, ruggedness and safety of the top mounted actuation indicator (TMAI) when used with Levalbuterol HFA MDI.
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, COPD
- Trial name
- NCT00583986
- Testing
- Levalbuterol HFA MDI with top mounted actuation indicator
- Where
- 26 sites in United States
- Volunteers
- 150 people
- Sponsor
- Sumitomo Pharma America, Inc.
Type 1 Diabetes
The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes
The purpose of this study is to learn whether an investigational automated insulin delivery system ("study system") for young children (2 yo to less than 6 yo) with type 1 diabetes can safely improve blood glucose (sometimes…
- Trial name
- NCT04796779
- Testing
- Tandem t:slim X2 with Control-IQ Technology Pro, Standard Care (SC), Tandem t:slim X2 with Control-IQ Technology V1.5
- Where
- 3 sites in United States
- Volunteers
- 102 people
- Sponsor
- Marc Breton
Asthma
Albuterol HFA MDI in Pediatric Participants With Asthma
The primary objective of this study is to evaluate the chronic-dose and efficacy of Albuterol-HFA-MDI relative to placebo in pediatric asthmatics.
- Trial name
- NCT00577655
- Testing
- Albuterol, Proventil® HFA
- Where
- 13 sites in United States
- Volunteers
- 103 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Bipolar Disorder, Anxiety Disorders
Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder
Pediatric Bipolar Disorder (BD) is uncommon in children. Its symptoms include periods of manic behavior (being overly happy or giddy, feeling grandiose, feeling a decreased need for sleep, having too much energy, moving more than…
- Conditions
- Bipolar Disorder, Anxiety Disorders, Bipolar Affective Disorder, Bipolar Depression
- Trial name
- NCT00805493
- Testing
- Riluzole
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Mental Health (NIMH)
Bronchial Asthma
Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma
To evaluate the efficacy and safety of GW815SF HFA MDI 25/50µg 1 inhalation bid in comparison with concomitant treatment with salmeterol xinafoate DPI 25µg 1 inhalation bid plus fluticasone propionate DPI 50µg 1 inhalation bid in…
- Trial name
- NCT00448435
- Testing
- GW815SF HFA MDI, salmeterol and fluticasone propionate
- Where
- 8 sites in Japan
- Volunteers
- 51 people
- Sponsor
- GlaxoSmithKline
Asthmatic Patients, MDI
Assessment of Emergency Spacers Versus Traditional Spacers for Delivery of Aerosolized Drugs
The goal of this clinical trial is to evaluate the performance, feasibility, and safety of emergency spacers compared to traditional spacers for the delivery of aerosolized drugs using pMDI.
- Conditions
- Asthmatic Patients, MDI, Aerosol Generating Procedure
- Trial name
- NCT06816342
- Testing
- Ventoline® Evohaler® 100 µg/inhalation pMDI alone, Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Able spacer, Ventoline® Evohaler® 100 µg/inhalation pMDI connectec to Tips-Haler spacer
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Beni-Suef University
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years of Age With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate the efficacy of insulin aspart compared to soluble human insulin on blood glucose control in children below 7 years of age with type 1 diabetes.
- Trial name
- NCT00571935
- Testing
- insulin aspart, soluble human insulin
- Where
- 5 sites in Poland
- Volunteers
- 61 people
- Sponsor
- Novo Nordisk A/S
Asthma
A Randomized Trial Comparing Metered Dose Inhalers and Breath Actuated Nebulizers
This study is determines if metered dose inhalers are as effective as breath actuated nebulizers for the treatment of mild to moderate asthma exacerbations in pediatric patients presenting to the emergency department.
- Trial name
- NCT02777125
- Testing
- Metered Dose Inhaler, Breath Actuated Nebulizer
- Volunteers
- 980 people
- Sponsor
- Le Bonheur Children's Hospital
Type 1 Diabetes, Multiple Daily Injections
Determination of Automated Multiple Insulin Dose Injections Settings Using the MDI/SMBG Advisor for Patients With Type 1 Diabetes -Data Collection, Observational & Proof of Concept Study
The MDI (Multiple Daily Injections) plus SMBG |(Self Monitoring Blood Glucose) Advisor (MPSA) is a software product that is designed to assist in insulin dosage decision making for subjects with T1DM using multiple daily…
- Trial name
- NCT04014569
- Testing
- MPSA Algorithm
- Where
- Israel
- Volunteers
- 6 people
- Sponsor
- Rabin Medical Center
Asthma
Effects of Ciclesonide MDI 50mg/Day and 200mg/Day (Ex-Valve) Once-Daily on Growth in Children With Mild Persistent Asthma
The primary objective is to determine if CIC 50 mg/day or 200 mg/day (ex-valve) administered once daily in the morning is non-inferior to placebo with respect to growth velocity in children with mild persistent asthma following a…
- Trial name
- NCT00270348
- Testing
- ciclesonide
- Volunteers
- 450 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
Smart MDI Study (CIP343)
The purpose of the study is to evaluate the effectiveness of the Smart MDI system with InPen™ and Simplera™ in comparison with Multiple Daily Injection (MDI) therapy with intermittent scanning or real-time Continuous Glucose…
- Trial name
- NCT06645834
- Testing
- Smart MDI System
- Where
- 18 sites in Belgium, Czechia and 4 more
- Volunteers
- 179 people
- Sponsor
- Medtronic MiniMed, Inc.
Asthma
A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma
This is a randomized, double-blind, placebo-controlled, multicenter, parallel group study to compare 2 dose levels of budesonide/albuterol BDA MDI (PT027) to its components budesonide BD MDI (PT008) and albuterol AS MDI (PT007)…
- Trial name
- DENALI (NCT03847896)
- Testing
- Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose), Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose), Budesonide metered dose inhaler / BD MDI 160 µg
- Where
- 129 sites in United States, Argentina and 5 more
- Volunteers
- 1,001 people
- Sponsor
- Bond Avillion 2 Development LP
Asthma
A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma
The study will measure the change in lung function in subjects with asthma after inhaling from either of two inhalers: Albuterol Spiromax® or placebo.
- Trial name
- NCT01424813
- Testing
- Albuterol MDPI
- Where
- 38 sites in United States
- Volunteers
- 158 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Type 1 Diabetes
Artificial Pancreas - Adolescent Physiology & Psychology Longitudinal Evaluation
This study designed to assess changes in control of Type 1 Diabetes in pubertal adolescents over a two year period. There are two arms/substudies, the first being a longitudinal randomized controlled trial and the second an…
- Trial name
- AP APPLE (NCT04510506)
- Testing
- Artificial Pancreas (AP)
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Virginia
Asthma
Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma
This study is a multicenter, stratified, randomized, active control, double-blinded, parallel-group comparative study with an open-label extension period.
- Trial name
- NCT02113436
- Testing
- FP/ SLM HFA MDI 50/25 mcg, FP HFA MDI 50 mcg
- Where
- 69 sites in Japan
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
Asthma
Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy
The aim of the study is to assess and compare efficacy and safety of BI 54903 at 3 doses twice daily (b.i.d.) and fluticasone propionate hydrofluoroalkane metered dose inhaler (HFA MDI) at a dose of 88 mcg b.i.d and placebo…
- Trial name
- NCT01397162
- Testing
- Fluticasone propionate, BI 54903
- Where
- 41 sites in United States
- Volunteers
- 29 people
- Sponsor
- Boehringer Ingelheim
Asthma
Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid
To investigate the efficacy of ciclesonide MDI either as once daily or a twice daily regimen in patients with mild to moderate asthma, who have previously been treated with an inhaled corticosteroid.
- Trial name
- NCT00174733
- Testing
- Ciclesonide (XRP1526)
- Where
- United States
- Volunteers
- 456 people
- Sponsor
- Sanofi
Type 1 Diabetes
Evaluation of Glycemic Changes During Exercise in Children With Type 1 Diabetes
The objectives of the study are: 1) to evaluate the effects of moderate exercise on SG evolution without insulin dose modification in patients with T1D under continuous subcutaneous insulin infusion (CSII) and multiple daily…
- Trial name
- TREAD-DIAB (NCT02824510)
- Testing
- Algorithmic changes in insulin therapy., Treadmill exercises, Insulin aspart, glargine and detemir
- Where
- Belgium
- Volunteers
- 24 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain